Skip to main content

Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Mintz Direct Featured Viewpoint

Mintz Direct

May 1, 2021

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.
Read More

Mintz Viewpoints

Showing 9 - 16 of 8794 results

News & Press Releases

News Thumbnail
In an article published by Law360, Mintz Member and Co-chair of the firm’s Securities Litigation Practice Jack Sylvia was quoted on the contentious legal battle between Massachusetts Secretary of the Commonwealth William Galvin and stock trading and investing app Robinhood, which is poised to test the state’s new fiduciary rule, and, by extension, the authority of one of the most aggressive securities regulators in the country.
News Thumbnail
Mintz Members Peter Cuomo and Muriel Liberto co-authored an article published in the March/April 2021 issue of IP Litigator that examined how the U.S. written description requirement is developing in the ‘unpredictable’ pharmaceutical and biotechnology-related arts. In their article, Mr. Cuomo and Dr. Liberto reviewed a line of post-Ariad “blaze marks” cases illustrating what may become a trend toward a higher bar for satisfying the written description requirement in the United States, particularly as applied to genus claims covering molecules large and small, such as antibodies, enzymes, and small organic molecules. Where the claim further relies upon functional language to define a genus of compounds, the authors cautioned that the bar is likely to be even higher to the extent this line of cases is followed.